Ligand Pharma (NASDAQ: LGND) reported Q2 EPS of $1.81, $1.41 better than the analyst estimate of $0.40. Revenue for the quarter came in at $18.42 million versus the consensus estimate of $17 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.